Provider of products, services and software solutions for protein research, has appointed professor Theodor Dingermann to its supervisory board
Dingermann has been managing director of the Institute for Pharmaceutical Biology, at the Johann Wolfgang Goethe-University, Frankfurt-am-Main since 1991.
His extensive experience in pharmaceutical research and development will support Protagen in its development and commercialisation of new analysis tools based on protein biochips.
Alongside his teaching responsibilities at the university, Dingermann has spent many years engaged in the commercialisation of scientific discoveries.
In 1985 he founded PharmaCon, an independent contract research organisation with a focus on anti-tumour therapy and he continues to work for the company as an associate/partner.
He also founded Phenion, a biological research business that specialises, among other things, in developing methods for in vitro testing that can help reduce the reliance on use of animals.
Dingermann currently sits on the supervisory board of Innovectis, a technology services company.
He was also a member of the supervisory board at Cilian between 2001 and 2005.
A member of numerous regulatory bodies, Dingermann chairs the biopharmaceuticals committee of the German regulatory authority, the BfArM, and has been on the scientific advisory board at the BfArM since 2007.
Dingermann is also editor-in-chief of the international journals, Die Pharmazie and Pharmazie in unserer Zeit, and has authored and edited many reference books in the areas of pharmaceuticals, biotechnology and pharmacy.
Commenting on the appointment, Christoph Huels, CEO Protagen, said: "We are delighted to announce the appointment of Professor Dingermann to the supervisory board.
"He is a well-known expert in the biotechnology and pharmaceutical industries, and his knowledge and expertise will be invaluable in the commercialisation of our protein biochip products".
Dingermann's appointment fills the sixth place on the board, which is a requirement of German law.
The board otherwise remains unchanged with Professor Axel Kleeman, a longstanding member of the executive board at Asta Medica, as chairman and Professor Helmut Meyer, co-founder of Protagen, as deputy chairman.
Capital market experts, Michael Motschmann, Gerhard Steinkamp and Holger Clemens Hinz make up the remaining three members.
